Phase I Study of MEK 162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors

Trial Profile

Phase I Study of MEK 162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Cancer; Glioma; Tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 09 Nov 2015 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top